“Build-To-Buy” Startup Model Alive And Kicking, Invested Execs Say
This article was originally published in The Pink Sheet Daily
Executive Summary
VCs and big pharma execs, speaking at CALBIO, said that even in today’s freer economic climate, investing early in startups, with an option to buy when the time is right, is still a viable business strategy.
You may also be interested in...
Regen Medicine Drives Big Uptick In 2015 Start-Up Dealmaking
Biotech start-ups cut deals at a rapid pace in 2015, signing almost twice the number of alliances done in 2014. Regenerative medicine was prominent in key partnerships.
Versant Continues “Build-To-Buy” With New Fund
Versant Ventures joined the ranks of venture capital firms closing new funds recently, thanks in part to the swell in biotech initial public offerings this year. Versant’s Fund V represents an oversubscribed level of approximately $55 million to its intended $250 million target.
GSK’s Venture Deal With Avalon Yields Three Start-Ups In Two Years
Silarus Therapeutics and Thyritope Biosciences are the latest two companies to be launched and financed by GlaxoSmithKline and partner Avalon Ventures. During Informa’s Pharmaceutical Strategy Conference, GSK’s Lon Cardon talked about how the partnership with Avalon is helping the Big Pharma access academic science.